Modified-release morphine or placebo for chronic breathlessness: the MABEL trial protocol

Date, Kathryn; Williams, Bronwen; Cohen, Judith; Chaudhuri, Nazia; Bajwah, Sabrina; Pearson, Mark; Higginson, Irene; Norrie, John; Keerie, Catriona; Tuck, Sharon; Hall, Peter; Currow, David; Fallon, Marie; Johnson, Miriam

Abstract

Chronic breathlessness, a persistent and disabling symptom despite optimal treatment of underlying causes, is a frightening symptom with serious and widespread impact on patients and their carers. Clinical guidelines support the use of morphine for the relief of chronic breathlessness in common long-term conditions, but questions remain around clinical effectiveness, safety and longer term (>7 days) administration. This trial will evaluate the effectiveness of low-dose oral modified-release morphine in chronic breathlessness. This is a multicentre, parallel group, double-blind, randomised, placebo-controlled trial. Participants (n=158) will be opioid-naïve with chronic breathlessness due to heart or lung disease, cancer or post-coronavirus disease 2019. Participants will be randomised 1:1 to 5 mg oral modified-release morphine/ placebo twice daily and docusate/placebo 100 mg twice daily for 56 days. Non-responders at Day 7 will dose escalate to 10 mg morphine/placebo twice daily at Day 15. The primary end-point (Day 28) measure will be worst breathlessness severity (previous 24 h). Secondary outcome measures include worst cough, distress, pain, functional status, physical activity, quality of life, and early identification and management of morphine-related side-effects. At Day 56, participants may opt to take open-label, oral modified-release morphine as part of usual care and complete quarterly breathlessness and toxicity questionnaires. The study is powered to be able to reject the null hypothesis and an embedded normalisation process theory-informed qualitative substudy will explore the adoption of morphine as a first-line pharmacological treatment for chronic breathlessness in clinical practice if effective.

Citation

Date, K., Williams, B., Cohen, J., Chaudhuri, N., Bajwah, S., Pearson, M., Higginson, I., Norrie, J., Keerie, C., Tuck, S., Hall, P., Currow, D., Fallon, M., & Johnson, M. (2023). Modified-release morphine or placebo for chronic breathlessness: the MABEL trial protocol. ERJ Open Research, 9(4), Article 00167. https://doi.org/10.1183/23120541.00167-2023

• Journal Article Type: Article
• Acceptance Date: May 13, 2023
• Online Publication Date: Aug 14, 2023
• Publication Date: Jul 1, 2023
• Deposit Date: Sep 29, 2023
• Publicly Available Date: Sep 29, 2023
• Journal: ERJ Open Research
• Electronic ISSN: 2312-0541
• Publisher: European Respiratory Society
• Peer Reviewed: Peer Reviewed
• Volume: 9
• Issue: 4
• Article Number: 00167
• DOI: https://doi.org/10.1183/23120541.00167-2023
• Public URL: https://hull-repository.worktribe.com/output/4372715